
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Commodore Capital
Deal Size : $69.4 million
Deal Type : Private Placement
Avalo Secures $69.4M From Full Exercise of Private Placement Warrants
Details : The proceeds will be used to advance AVTX-009, an anti-IL-1β antibody targeting inflammatory diseases, in development for the treatment of hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 12, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Commodore Capital
Deal Size : $69.4 million
Deal Type : Private Placement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avalo Doses First Patient in AVTX-009 Phase 2 LOTUS Trial For Hidradenitis
Details : AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1 beta, being developed for moderate to severe hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 08, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVTX-009 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avalo Therapeutics Gets Active IND for AVTX-009 in Hidradenitis Suppurativa
Details : AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1 beta, being developed for moderate to severe hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Avalo Therapeutics
Deal Size : $185.0 million
Deal Type : Private Placement
Avalo Acquires Anti-IL-1β mAb and Announces Financing of up to $185 Million
Details : The net proceeds will be used for the developement of AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $115.6 million
March 27, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Avalo Therapeutics
Deal Size : $185.0 million
Deal Type : Private Placement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Avalo Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Avalo Acquires Anti-IL-1β mAb and Announces Up to $185 Million Private Placement
Details : Through the acquisition of AlmataBio, Avalo acquires Phase 2-ready, AVTX-009, a humanized monoclonal antibody (IgG4) that binds to interleukin-1β, being developed for hidradenitis suppurativa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : AVTX-009
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Avalo Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alpha-D-Galactose
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : AUG Therapeutics
Deal Size : $45.1 million
Deal Type : Divestment
Avalo Enters into Agreement to Divest AVTX-800 Series
Details : Under the divestiture, AUG gains rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose). AVTX-801 is a therapeutic dose of D-galactose currently in development for the treatment of phosphogl...
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : $0.1 million
September 12, 2023
Lead Product(s) : Alpha-D-Galactose
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : AUG Therapeutics
Deal Size : $45.1 million
Deal Type : Divestment

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVTX-002 (quisovalimab) is a fully human monoclonal antibody (mAb), directed against human LIGHT, and investigated for the treatment of patients with poorly controlled non-eosinophilic asthma
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : SVB Securities
Deal Size : $15.0 million
Deal Type : Public Offering
Details : AVTX-002 is a fully human monoclonal antibody, directed against human LIGHT. AVTX-002 is currently in Phase 2 development for non-eosinophilic asthma (NEA) with proof-of-concept data in inflammatory bowel diseases (IBD) and COVID-19 acute respiratory dis...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
February 02, 2023
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : SVB Securities
Deal Size : $15.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AVTX-002 is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Quisovalimab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
